We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

126 hedge funds and large institutions have $1.62B invested in Recursion Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 52 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

420% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 10

382% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 11

132% more call options, than puts

Call options by funds: $2.03M | Put options by funds: $878K

100% more funds holding in top 10

Funds holding in top 10: 4 → 8 (+4)

50% more funds holding

Funds holding: 84 → 126 (+42)

28% more capital invested

Capital invested by funds: $1.26B → $1.62B (+$352M)

24.61% more ownership

Funds ownership: 34.53% → 59.14% (+25%)

Holders
126
Holders Change
+42
Holders Change %
+50%
% of All Funds
1.94%
Holding in Top 10
8
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
53
Increased
52
Reduced
10
Closed
11
Calls
$2.03M
Puts
$878K
Net Calls
+$1.16M
Net Calls Change
+$101K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$94M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$64M
3
State Street
State Street
Massachusetts
+$56.7M
4
AI
ArchPoint Investors
Florida
+$23.6M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$23.3M

Top Sellers

Rank Fund Capital Flow
1
CL
CRV LLC
California
-$16.9M
2
Alkeon Capital Management
Alkeon Capital Management
New York
-$12.6M
3
YRHAM
Yong Rong (HK) Asset Management
Hong Kong
-$8.68M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.09M
5
AIM
ARK Investment Management
Florida
-$6.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Lazard Asset Management
51
Lazard Asset Management
New York
$2.46M +$2.7M +143,384 New
CAM
52
Cresset Asset Management
Illinois
$2.29M +$2.51M +133,437 New
Goldman Sachs
53
Goldman Sachs
New York
$2.12M +$1.97M +104,919 +562%
KAS
54
Kemnay Advisory Services
New York
$2.08M +$2.29M +121,573 New
RhumbLine Advisers
55
RhumbLine Advisers
Massachusetts
$2.04M +$1.76M +93,790 +371%
Morgan Stanley
56
Morgan Stanley
New York
$1.98M +$1.99M +105,801 +1,091%
MCCP
57
Mission Creek Capital Partners
California
$1.92M +$2.1M +111,850 New
California State Teachers Retirement System (CalSTRS)
58
California State Teachers Retirement System (CalSTRS)
California
$1.65M +$1.53M +81,132 +534%
SRAM
59
Spouting Rock Asset Management
Pennsylvania
$1.54M +$703K +37,352 +71%
Swiss National Bank
60
Swiss National Bank
Switzerland
$1.5M +$1.65M +87,600 New
Deutsche Bank
61
Deutsche Bank
Germany
$1.25M +$1.05M +56,039 +334%
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
$1.16M +$999K +53,114 +369%
AIG
63
American International Group
New York
$1.05M +$863K +45,851 +298%
SG
64
StepStone Group
California
$1.02M +$1.12M +59,763 New
Squarepoint
65
Squarepoint
New York
$984K +$1.08M +57,457 New
TD Asset Management
66
TD Asset Management
Ontario, Canada
$881K +$203K +10,800 +27%
Wells Fargo
67
Wells Fargo
California
$868K +$953K +50,632 +389,477%
ProShare Advisors
68
ProShare Advisors
Maryland
$816K +$897K +47,649 New
Invesco
69
Invesco
Georgia
$745K +$818K +43,473 New
VOYA Investment Management
70
VOYA Investment Management
Georgia
$734K +$594K +31,591 +281%
MIM
71
MetLife Investment Management
New Jersey
$706K +$573K +30,451 +283%
PPA
72
Parametric Portfolio Associates
Washington
$656K +$720K +38,291 New
TC
73
Titleist Capital
Texas
$643K +$707K +37,550 New
BCM
74
Bienville Capital Management
New York
$626K +$688K +36,563 New
Principal Financial Group
75
Principal Financial Group
Iowa
$608K +$667K +35,471 New
1 2
3
4 5

RXRX Hedge Fund Activity: Q4 2021 in Review

126 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2021, worth a combined $1.62B — up 28% from $1.26B a quarter earlier.

Buyers outnumbered sellers: 53 funds opened new RXRX positions and 11 closed out — a net gain of 42 holders — while 52 added to existing stakes and 10 trimmed.

The largest buyer was BlackRock, adding an estimated $94M. The largest seller was CRV LLC, exiting entirely with an estimated $16.9M sold.

  • 126 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2021, up from 84 in Q3 2021.
  • Funds reported $1.62B of Recursion Pharmaceuticals stock for Q4 2021, up 28% quarter-over-quarter.
  • 53 funds opened new Recursion Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +42 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $94M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2021 was CRV LLC, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2021.